President Donald Trump needs to leave medical treatment and advice to the nation's doctors. Wielding the bully pulpit as he did over the weekend to promote hydroxychloroquine as a breakthrough COVID-19 drug is premature and potentially harmful.
This is not a medication for Americans to take on their own or insist upon over all other drugs should they become ill with this mysterious new virus. Political pronouncements are not a substitute for medical expertise.
Sold under the name Plaquenil, hydroxychloroquine is in the spotlight because there is no medication approved through regular channels to treat COVID-19. Doctors are rifling through the existing pharmaceutical toolbox to find something that may help.
Hydroxychloroquine is one drug that's under consideration. It's been used since the 1950s to treat lupus and is also a malaria preventive. But it's not the only candidate that may hold promise.
Remdesivir, an antiviral developed to treat Ebola, was used successfully to treat one of the first Americans infected with COVID-19. Losartan, a high blood pressure medication that may block the COVID-19 virus from entering human cells, could also have benefits.
At this point, it's too soon to call any of these drugs a "game changer," Dr. Tim Schacker of the University of Minnesota told an editorial writer in a recent interview.
Large clinical trials are underway here and elsewhere to determine what works best. That means doctors are providing cutting-edge treatments to those who become ill and swiftly analyzing results. This work is accelerated, but it's not clear if one drug works or if it's better than others.
The small studies of hydroxychloroquine that have been done so far are not a replacement for rigorous trials at academic medical centers like the U. That the results from this early, limited research on hydroxychloroquine are mixed underscores the need to scale-up scientific scrutiny.